Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Phil A. Hart, Georgios I. Papachristou, Walter G. Park, Anne‐Marie Dyer, Vernon M. Chinchilli, Elham Afghani, Venkata S. Akshintala, Dana K. Andersen, James Buxbaum, Darwin L. Conwell, Kathleen Dungan, Jeffrey J. Easler, Evan L. Fogel, Carla J. Greenbaum, Rita R. Kalyani, Murray Korc, Richard A. Kozarek, Maren R. Laughlin, Peter J. Lee, Jennifer Maranki, Stephen J. Pandol, Anna Evans Phillips, José Serrano, Vikesh K. Singh, Cate Speake, Temel Tirkes, Frederico G. S. Toledo, Guru Trikudanathan, Santhi Swaroop Vege, Ming Wang, Cemal Yazıcı, Atif Zaheer, Christopher E. Forsmark, Melena D. Bellin, Dhiraj Yadav
Abstract
ABSTRACT: Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.